Stockscreener 앱 받기
0.224
6.57%
0.0138
시간 외 거래:
.21
-0.014
-6.25%
전일 마감가:
$0.2102
열려 있는:
$0.2144
하루 거래량:
559.56K
Relative Volume:
0.82
시가총액:
$15.18M
수익:
$9.14M
순이익/손실:
$-124.31M
주가수익비율:
-0.234
EPS:
-0.9573
순현금흐름:
$-125.43M
1주 성능:
+3.37%
1개월 성능:
-28.18%
6개월 성능:
-84.34%
1년 성능:
-91.11%
1일 변동 폭
$0.2112
$0.2336
1주일 범위
$0.2014
$0.2454
52주 변동 폭
$0.2014
$2.55
Tscan Therapeutics Inc Stock (TCRX) Company Profile
명칭
Tscan Therapeutics Inc
전화
857-399-9500
주소
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.224 | 15.18M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
514.65 | 130.44B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
242.08 | 96.65B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
807.48 | 83.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
869.72 | 54.69B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
384.50 | 43.50B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-08 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | 개시 | BTIG Research | Buy |
| 2024-05-13 | 개시 | Needham | Buy |
| 2023-06-22 | 개시 | Wedbush | Outperform |
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
Form PRE 14A Tscan Therapeutics Inc For: 16 October By Investing.com - Investing.com Nigeria
A CEO receives stock with 75% conditionally vesting on a trial milestone or in 2030 at TScan Therapeutics (TCRX). - Stock Titan
CFO and medical chief will leave by November 1, 2026, at TScan Therapeutics (TCRX). - Stock Titan
Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). - Stock Titan
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
TScan Therapeutics announces retention program for key executives - Investing.com
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com Australia
TScan Therapeutics Launches Executive Retention Incentive Program - TipRanks
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com India
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com India
TScan Therapeutics announces retention program for key executives By Investing.com - Investing.com UK
TScan Therapeutics announces retention program for key executives - Investing.com
TScan Therapeutics grants retention awards to CEO Gavin MacBeath and CLO Zoran Zdraveski - TradingView
New milestone-tied pay plan for TScan Therapeutics (TCRX) leaders - Stock Titan
Form 8K Tscan Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
TSCAN THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TARGET PRICE TO $1 FROM $7 - webull.com
H.C. Wainwright Downgrades TScan Therapeutics(TCRX.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com Canada
H.C. Wainwright downgrades Tscan stock rating on restructuring - Investing.com India
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com UK
H.C. Wainwright downgrades Tscan stock rating on restructuring By Investing.com - Investing.com South Africa
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme StudySlideshow (NASDAQ:TCRX) 2026-09-04 - Seeking Alpha
TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors - BioPharm International
TCRX Downgraded by Wedbush -- Price Target Lowered to $1.00 - GuruFocus
Tscan prioritizes in vivo solid tumor program - BioWorld News
TScan Therapeutics IncExpects to Incur Abo - Moomoo
TScan Therapeutics sheds majority of staff, pauses Phase 3 trial amid funding shortfall - The Business Journals
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Nigeria
Crude Oil Moves Higher; US Factory Orders Rise In July - Benzinga
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com South Africa
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com Canada
Tscan Therapeutics stock rating cut to neutral by Wedbush on strategy shift - Investing.com UK
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Why is TScan Therapeutics stock collapsing today? By Investing.com - Investing.com UK
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Yahoo Finance
TScan Therapeutics Restructures to Focus on Solid Tumors - TipRanks
TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - GlobeNewswire
Why is TScan Therapeutics stock collapsing today? - Investing.com
TScan Therapeutics highlights push into in vivo-engineered TCR-T cell therapy for solid tumors in corporate presentation - Bitget
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Barchart.com
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportSell Signal Alerts - dars.gov.et
TScan Therapeutics (TCRX) Holds at $0.75 as Biotech Stock Defends Key SupportWave Extension - vinanet.vn
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Yahoo Finance
Is Amgen (AMGN) Refocusing Its R&D Portfolio With The Exit From TScan’s Crohn’s Deal? - simplywall.st
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy - Fierce Biotech
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
Tscan Therapeutics Inc (TCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tscan Therapeutics Inc 주식 (TCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
1.08%
2.09%
자본화:
|
볼륨(24시간):